| Literature DB >> 31652871 |
Rhea Lewis1,2, Andrei Sorin Bolocan3,4, Lorraine A Draper5,6, R Paul Ross7,8, Colin Hill9,10.
Abstract
Changing consumer attitudes show an increased interest in non-chemical antimicrobials in food preservation and safety. This greater interest of consumers in more 'natural' or 'clean-label' food interventions is complicated by concurrent demands for minimally processed, ready-to-eat (RTE) foods with long shelf lives. Two viable interventions are bacteriophage (phage) and bacteriocins, a number of which have already been approved for use in food safety. Listeriosis is a serious foodborne infection which affects at-risk members of the population. Listeriosis incidence has increased between 2008 and 2015 and has a case fatality rate of up to 20% with antibiotic intervention. Here, we tested an intervention to attempt to control a pathogenic Listeria monocytogenes strain in a food model using two of these alternative antimicrobials. Phage P100 on its own had a significant effect on L. monocytogenes ScottA numbers in coleslaw over a 10-day period at 4 °C (p ≤ 0.001). A combination of P100 and Nisaplin® (a commercial formulation of the lantibiotic bacteriocin, nisin) had a significant effect on the pathogen (p ≤ 0.001). P100 and Nisaplin® in combination were more effective than Nisaplin® alone, but not P100 alone.Entities:
Keywords: Listeria monocytogenes; bacteriocin; food safety; phage
Year: 2019 PMID: 31652871 PMCID: PMC6893746 DOI: 10.3390/v11110977
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Listeria strains used and their sensitivity to phage P100. Efficiency of plaquing is represented as a fraction with standard error of the mean (SEM) of three separate experiments. If no P100 plaques formed on a strain, efficiency of plaquing is represented by (-).
| Strain | Equivalent Names | Origin | Serotype | Efficiency of Plaquing of P100 |
|---|---|---|---|---|
| Guinea pig [ | 1/2a | 1.22 ± 0.4 | ||
| ATCC 19117 | Animal [ | 4d | 1 ± 0 | |
| ATCC 19118 | Animal [ | 4e | 0.92 ± 0.54 | |
| - | 0.83 ± 0.25 | |||
| 20240-954 | Animal [ | 1/2b | 0.72 ± 0.31 | |
| F2365, JI-119, TS43 | California outbreak, 1985 [ | 4b | 0.70 ± 0.03 | |
| 33013 | Clinical (Massachusetts | 4b | 0.70 ± 0.03 | |
| Rabbit [ | 1/2a | 0.61 ± 0.2 | ||
| RM2218 | Food [ | 4b | 0.59 ± 0.22 | |
| 20674-01 | Animal [ | 1/2b | 0.49 ± 0.25 | |
| Rabbit [ | 1/2c | 0.29 ± 0.02 | ||
| Human CSF [ | 1/2c | 0.24 ± 0.06 | ||
| Cheese; | 1/2a | 0.002 ± 0.001 | ||
| ATCC 25400 | Corn stalks [ | - | - | |
| OB001102 | Food [ | 1/2b | - | |
| - | - |
Figure 1(A) Effect of P100 on ScottA reduction in coleslaw stored at 4 °C over a 10-day period. Error bars represent SEM. Coleslaw was spiked with bacteria (7.1 × 105 CFU/g) and phage (4.0 × 107 PFU/g). (B) P100 titre was also measured throughout the experiment.
ScottA CFU/mL during P100 and Nisaplin® checkerboard assay in coleslaw. MIC of P100 alone and Nisaplin® alone are shown in bold. FIC values were calculated. FIC index results are interpreted as follows: FIC ≤ 0.5 is synergy, 0.5 < FIC ≤ 0.75 is partial synergy, 0.75 < FIC ≤ 1.0 is additive, FIC > 1.0 is indifferent, and FIC > 4 is antagonistic. The partially synergistic combination of P100 and Nisaplin® is shown in red.
| Antimicrobial Concentration | P100 | P100 | P100 | P100 | P100 |
|---|---|---|---|---|---|
| MOI 0 | MOI 0.01 | MOI 0.1 | MOI 1 | MOI 10 | |
| Nisaplin® | 9.6 × 105 | 1.2 × 106 | 1.1 × 106 | 1.3 × 105 |
|
| Nisaplin® | 5.0 × 105 | 4.6 × 105 | 6.8 × 105 | 6.2 × 104 | <1.0 × 104 |
| Nisaplin® | 4.2 × 104 | 8.0 × 104 | 2.0 × 104 |
| <1.0 × 104 |
| Nisaplin® |
| <1.0 × 104 | <1.0 × 104 | <1.0 × 104 | <1.0 × 104 |
| Nisaplin® | <1.0 × 104 | <1.0 × 104 | <1.0 × 104 | <1.0 × 104 | <1.0 × 104 |
Figure 2(A) Effect of P100 and Nisaplin® in combination on ScottA reduction in coleslaw stored at 4 °C over a 10-day period. Coleslaw was spiked with bacteria (9.4 × 105 CFU/g) and phage (~2.6 × 106 PFU/g). Error bars represent SEM. P100 titre was also measured throughout the experiment of (B) P100 MOI 2.5 alone and (C) P100 MOI 2.5 and Nisaplin® 25 µg/mL in combination.